<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334229</url>
  </required_header>
  <id_info>
    <org_study_id>IIS#39262</org_study_id>
    <nct_id>NCT01334229</nct_id>
  </id_info>
  <brief_title>Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes</brief_title>
  <acronym>JANUB48</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Sitagliptin on the Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and Apolipoprotein B100 in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has
      been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes
      mainly through incretin hormone-mediated improvements in islet function [13]. Although
      clinical studies to date indicate that fasting lipid levels are minimally affected by DPP-IV
      inhibitor treatment [14-16], animal studies suggested that DPP-IV inhibition reduce
      intestinal triglycerides (TG) absorption and apolipoprotein (apo) production [17] and
      increased chylomicron catabolism [18]. Interestingly, a recent study supporting this
      hypothesis showed that vildagliptin therapy was able to reduce postprandial intestinal
      triglyceride-rich lipoproteins (TRL) particles in patients with type 2 diabetes [19].
      Recently, our group has reported that sitagliptin treatment significantly reduced plasma apo
      B-48 and TG concentrations in the postprandial state. Moreover, animal studies showed that
      sitagliptin decreased intestinal secretion of intestinal apo B-48, mainly by increasing level
      of glucagon-like peptide (GLP)-1 [20]. Therefore, the present study was designed to examine
      the effects of sitagliptin on the kinetics of TRL apo B-48 and in patients with type 2
      diabetes. A possible reduction in postprandial atherogenic TRL apo B-48-containing
      lipoprotein levels by sitagliptin would add to therapeutic utility of this DPP-4 inhibitor
      and suggest the potential to reduce cardiovascular risk in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Glucagon-like Peptide-1 by ELISA</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Glucose</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Insulin</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Pool Sizes With Stable Isotope During Postprandial Period</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100 mg/d for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg/d for 6 weeks</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 18 to 65 years of age.

          -  Post-menopausal women under age 65 on stable medical therapy for 6 months before the
             study (the patient should have demonstrated stable lipid panels)

          -  Women should not be on hormone replacement therapy (no recent starting or stopping)

          -  Type 2 diabetes as defined by the American Diabetes Association.

          -  Non-smoker.

          -  Body mass index between 25.0 and 40.0 kg/m2.

          -  Baseline glycated hemoglobin A1c (HbA1c) between 6.5 and 8.5%.

          -  Baseline fasting plasma glucose &lt; 15.0 mmol/L.

          -  Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at screening
             and week -4.

          -  Patients having received stable doses of metformin for at least 3 months before
             randomization.

          -  Subjects must be willing to give written informed consent and able to adhere to dosing
             schedule, visit schedule and phone follow-up assessment.

          -  Patients should be otherwise generally healthy, without elevations in hepatic
             transaminases or abnormal renal function or coagulation.

          -  Patients having normal thyroid stimulating hormone at screening

        Exclusion Criteria:

          -  Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be
             excluded.

          -  Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic
             complications will be excluded.

          -  Patients having received or being treated with insulin or a thiazolidinedione within
             the past 6 months will be excluded.

          -  Patients taking any other hypoglycemic agent, other than metformin.

          -  Subjects will be excluded if they have cardiovascular disease (coronary heart disease,
             cerebrovascular disease or peripheral arterial disease) or if they are taking other
             medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers,
             thiazide diuretics, lipid lowering agents, significant alcohol intake etc.).

          -  Subjects who are in a situation or have any condition that, in the opinion of the
             investigator, may interfere with optimal participation in the study.

          -  Individuals with a history of mental instability, drug or alcohol abuse or individuals
             who have been treated or are being treated for severe psychiatric illness that, in the
             opinion of the investigator, may interfere with optimal participation in the study.

          -  History of alcohol or drug abuse within the past 2 years. Patients must not take
             alcohol during the study.

          -  Disorders of the hematologic, digestive, or central nervous systems, including
             cerebrovascular disease and degenerative disease, that would limit study evaluation or
             participation.

          -  Known impairment of renal function (serum creatinine levels &gt; 1.7 mg/dL for men),
             dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3
             ± 1 g).

          -  Active or chronic hepatobiliary or hepatic disease. In addition, patients with
             aspartate aminotransferase or alanine aminotransferase &gt;2 x upper limit of the
             laboratory reference range will be excluded.

          -  Subjects with coagulopathy (prothrombin time or partial thromboplastin time at Visit 1
             &gt;1.5 times control).

          -  Subjects with hemoglobin &gt;2 x the lower limit of the laboratory reference range will
             be excluded.

          -  Patients who are known to have tested positive for human immunodeficiency virus (HIV).

          -  Patients who are currently enrolled in another clinical study.

          -  Patients who have used any investigational drug within 30 days of the first clinic
             visit.

          -  Congestive heart failure New York Heart Association (NYHA) Class III or IV.
             Uncontrolled cardiac arrhythmias within 3 months of study entry.

          -  Uncontrolled diabetes mellitus (HbA1c&gt;8.5%) or other endocrine or metabolic disease
             known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on
             replacement doses of thyroid hormone are eligible for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Couture, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>September 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2014</results_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Patrick Couture</investigator_full_name>
    <investigator_title>MD, PhD, FRCP</investigator_title>
  </responsible_party>
  <keyword>sitagliptin</keyword>
  <keyword>diabetes</keyword>
  <keyword>apolipoprotein B48 and B100</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin Then Placebo</title>
          <description>First intervention: Sitagliptin 100 mg/d for 6 weeks Washout: 4 weeks Second intervention: Placebo for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First Then Sitagliptin</title>
          <description>First intervention: Placebo for 6 weeks Washout: 4 weeks Second intervention: Sitagliptin 100 mg/d for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin First Then Placebo</title>
          <description>First intervention: Sitagliptin 100 mg/d for 6 weeks Washout: 4 weeks Second intervention: Pacebo for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo First Then Sitagliptin</title>
          <description>First intervention: Placebo for 6 weeks Washout: 4 weeks Second intervention: Sitagliptin 100 mg/d for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="4.6"/>
                    <measurement group_id="B2" value="59" spread="2.9"/>
                    <measurement group_id="B3" value="58.2" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period</title>
          <units>mg/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apolipoprotein B48 production rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.7"/>
                    <measurement group_id="O2" value="2.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein B100 production rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="8.4"/>
                    <measurement group_id="O2" value="30.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Glucagon-like Peptide-1 by ELISA</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Glucagon-like Peptide-1 by ELISA</title>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="6.8"/>
                    <measurement group_id="O2" value="3.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Glucose</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="1.2"/>
                    <measurement group_id="O2" value="8.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Insulin</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Insulin</title>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.1" spread="91.7"/>
                    <measurement group_id="O2" value="179.5" spread="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Pool Sizes With Stable Isotope During Postprandial Period</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Pool Sizes With Stable Isotope During Postprandial Period</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apolipoprotein B48 pool size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="25.8"/>
                    <measurement group_id="O2" value="48.5" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein B100 pool size</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488.0" spread="210.2"/>
                    <measurement group_id="O2" value="537.8" spread="232.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period</title>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Apolipoprotein B48 and Apolipoprotein B100 Fractional Catabolic Rates With Stable Isotope During Postprandial Period</title>
          <units>pools/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apolipoprotein B48 fractional catabolic rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="2.5"/>
                    <measurement group_id="O2" value="6.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apolipoprotein B100 fractional catabolic rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.3"/>
                    <measurement group_id="O2" value="5.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo for 6 weeks
Placebo: Placebo for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg/d for 6 weeks
Sitagliptin: Sitagliptin 100 mg/d for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Patrick Couture MD, PhD, FRCP</name_or_title>
      <organization>Laval University</organization>
      <phone>418-654-2106</phone>
      <email>patrick.couture@crchul.ulaval.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

